TAKEDA MAY AXE TAVOCEPT DEAL FOLLOWING POOR RESULTS

Takeda Pharmaceutical has informed BioNumerik Pharmaceuticals that it is considering terminating their alliance over Tavocept after the drug candidate failed to meet the primary endpoints of two Phase III trials in cancer patients.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=619226D1-4177-43E0-BFCC-965A9C980939)